132 related articles for article (PubMed ID: 34291633)
1. Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma.
Uehling DE; Joseph B; Chung KC; Zhang AX; Ler S; Prakesch MA; Poda G; Grouleff J; Aman A; Kiyota T; Leung-Hagesteijn C; Konda JD; Marcellus R; Griffin C; Subramaniam R; Abibi A; Strathdee CA; Isaac MB; Al-Awar R; Tiedemann RE
J Med Chem; 2021 Aug; 64(15):11129-11147. PubMed ID: 34291633
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
Ding HW; Deng CL; Li DD; Liu DD; Chai SM; Wang W; Zhang Y; Chen K; Li X; Wang J; Song SJ; Song HR
Eur J Med Chem; 2018 Feb; 146():460-470. PubMed ID: 29407971
[TBL] [Abstract][Full Text] [Related]
3. Protein expression and purification of G-protein coupled receptor kinase 6 (GRK6), toward structure-based drug design and discovery for multiple myeloma.
Olson TL; Zhang S; Labban D; Kaschner E; Aceves M; Iyer S; Meza-Aguilar JD; Zook JD; Chun E; Craciunescu FM; Liu W; Shi CX; Stewart AK; Hansen DT; Meurice N; Fromme P
Protein Expr Purif; 2021 Sep; 185():105890. PubMed ID: 33971243
[TBL] [Abstract][Full Text] [Related]
4. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.
Tiedemann RE; Zhu YX; Schmidt J; Yin H; Shi CX; Que Q; Basu G; Azorsa D; Perkins LM; Braggio E; Fonseca R; Bergsagel PL; Mousses S; Stewart AK
Blood; 2010 Feb; 115(8):1594-604. PubMed ID: 19996089
[TBL] [Abstract][Full Text] [Related]
5. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
Hou W; Ren Y; Zhang Z; Sun H; Ma Y; Yan B
Bioorg Med Chem; 2018 May; 26(8):1740-1750. PubMed ID: 29523467
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies.
Elkamhawy A; Park JE; Cho NC; Sim T; Pae AN; Roh EJ
J Enzyme Inhib Med Chem; 2016; 31(1):158-66. PubMed ID: 25807298
[TBL] [Abstract][Full Text] [Related]
8. Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
Song J; Jang S; Lee JW; Jung D; Lee S; Min KH
Bioorg Med Chem Lett; 2019 Feb; 29(3):477-480. PubMed ID: 30554954
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
[TBL] [Abstract][Full Text] [Related]
10. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
Yassen AS; Elshihawy HE; Said MM; Abouzid KA
Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors.
Zhao H; Hu X; Cao K; Zhang Y; Zhao K; Tang C; Feng B
Eur J Med Chem; 2018 Sep; 157():935-945. PubMed ID: 30165341
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
13. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
[TBL] [Abstract][Full Text] [Related]
14. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of quinazolines as tyrosine kinase inhibitors.
Srivastava SK; Kumar V; Agarwal SK; Mukherjee R; Burman AC
Anticancer Agents Med Chem; 2009 Mar; 9(3):246-75. PubMed ID: 19275520
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments.
Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L
Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors.
Jin H; Wu BX; Zheng Q; Hu CH; Tang XZ; Zhang W; Rao GW
Future Med Chem; 2021 Apr; 13(7):601-612. PubMed ID: 33685233
[No Abstract] [Full Text] [Related]
19. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]